Caxton Associates Discloses 6.1% Stake in CollaGenex (CGPI)
More News related to CGPI
- CollaGenex Pharmaceuticals (CGPI) Reports Q4 EPS of $0.02
- Caxton Associates Discloses 6.1% Stake in CollaGenex (CGPI)
- Roth Capital Downgrades CollaGenex (CGPI) to Hold
- Wachovia Downgrades CollaGenex (CGPI) to Market Perform
- Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
In a 13G filing on CollaGenex Pharmaceuticals Inc. (Nasdaq: CGPI) after the close, Caxton Associates disclosed a 6.1% stake (1,300,000 shares) in the company. The firm did not show a stake in CollaGenex at the quarter ended 12/31/07.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
Caxton Associates, L.L.C., is a $14 billion New York-based hedge fund, founded in 1983 by Bruce Kovner.
Related Categories
13GsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
